Safety evaluation of third-generation oncolytic HSV-1 G47-delta in patients with castration resistant prostate cancer.

Trial Profile

Safety evaluation of third-generation oncolytic HSV-1 G47-delta in patients with castration resistant prostate cancer.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs DS 1647 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jun 2016 New trial record
    • 10 May 2016 Safety results of first two cohorts presented at the 111th Annual Meeting of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top